One of the pillars of drug discovery programs is the selection of a predictive preclinical model. The system, stimulus and readout should be of the highest possible clinical relevance to develop a good predictive model and help decreasing the drug attrition rate.In this webinar we explain how patient-specific and genetically modified iPSC-derived cells can be utilized to develop relevant assays for high-throughput phenotypic screening. We present how iPSC-derived cardiomyocytes can be applied to perform fully automated phenotypic high-throughput screening in a model of hypertrophic cardiomyopathy.
How to select relevant cellular models suitable for phenotypic high-throughput screening
Parameters to be considered for your assay development
Key considerations for lead selection and validation